Insight

Jun 1, 2024, 10:00

Tom Powles: TROPICS-4 in heavily pretreated bladder cancer missed OS

Tom Powles, Director of Barts Cancer Center, shared on X:

“TROPICS-4 (sacituzumab, govitecan versus chemo) in heavily pretreated bladder cancer missed OS.
Many drugs have failed in this space (personal experience).

Managing toxicity is important. Earlier treatment and combinations may yield different results.”

Additional information.
Source: Tom Powles/X

Barts Cancer Center bladder cancer cancer govitecan OncoDaily Oncology Sacituzumab Tom Powles TROPICS-4

IMvigor011 Trial Reports ctDNA as Predictor of Response to Adjuvant Atezolizumab in Bladder Cancer

Ruben Mesa is Starting a New Position as President of Cancer National Service Line at Advocate Health

Patrick Soon-Shiong: 30 Years and $3B Toward a Universal Cancer Fighter

Dana Dornsife: After 19 Years, Lazarex Cancer Foundation Is Shuttering Because of Lack of Funding

Matt Sherer: ASCO Supports Permanent Medicare Telehealth

Special Coverage

Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
ESMO 2024 Congress
September 13-17, 2024
ASCO Annual Meeting
May 30 - June 4, 2024
Yvonne Award 2024
May 31, 2024
OncoThon 2024, Online
Feb. 15, 2024
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023

Facebook

Youtube

Voices

Aug 19, 2025, 18:05

Guru Sonpavde: Cutting-Edge and Emerging Therapies Reported at ASCO25 and GU25

Career Updates

Aug 19, 2025, 18:04

Eric Edison Gardner Received the 2025 Young Investigator Award - IASLC

Voices

Aug 19, 2025, 17:56

Devika Das: Updates and Opportunities in Multidisciplinary Care of Lung Cancer in Mississippi

Societies

Aug 19, 2025, 17:50

The Max Foundation and PQMD: Advancing Access to Care Through Global Partnerships

Voices

Aug 19, 2025, 17:29

Norman Ng: How Should Hong Kong Respond to the Challenge of Innovative Drug Pricing?

Career Updates

Aug 19, 2025, 17:17

Bryan Schneider Named Associate Dean for Clinical Trials at IU School of Medicine

Voices

Aug 19, 2025, 17:00

Rahul Gosain: TROPION-Lung01 and Lung05 Study that Resulted in DatoDXd FDA Approval

Societies

Aug 19, 2025, 16:53

European Commission Approved Nirogacestat for Desmoid Tumors - Merck Healthcare

Science

Aug 19, 2025, 16:41

NOTCH1 Reactivates STING to Reverse Immune Suppression in SCLC - NCI Center for Cancer Research

Societies

Aug 19, 2025, 16:34

The Max Foundation and KCMH: Expanding Access to Life-Saving Care in Thailand

Voices

Aug 19, 2025, 16:27

Celia Diez de los Rios: Journal Club Reflection on Patient Engagement

Voices

Aug 19, 2025, 16:17

Zahra Ramji: CHALLENGE Study Shows Exercise Improves Survival in Colon Cancer